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investigate which parameters were related to the patients‘ 
opinion about cosmesis. In addition, we analyzed whether 
firmness, presence of rib pain or quality of life (QoL) aspects 
(EORTC QLQ C-30 questionnaire) at 4 years were related to 
the patients’ opinion on cosmetic outcome.  
 
Results: Of the 7 BCCT.core parameters, pBCE and pBCD 
were significantly related to patients’ score at 4 years. 
Patients with any difference in firmness rated their cosmesis 
worse than patients without any difference, even when the 
objective score (i.e. BCCT.core) was similar. This effect was 
larger by increasing difference. Worse perception of cosmetic 
outcome was also independently related to lower global QoL, 
lower emotional functioning and higher scores in the 
depression scale. The presence of rib pain had no influence. 
 
Conclusion: The patients‘ opinion on cosmetic outcome was 
significantly related to objective parameters like distance 
from nipple to inframammary fold (pBCE) and length of 
breast contour (pBCD), but also to subjective factors, i.e. 
severity of firmness, depressive feelings, global QoL and 
emotional functioning. 
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Purpose or Objective: The primary endpoint of this phase II 
study was to determine the progression-free survival (PFS) of 
oligometastatic breast cancer patients treated with radical 
radiotherapy to all metastatic sites. 
 
Material and Methods: Patients affected by oligometastatic 
breast cancer were enrolled in this phase II trial. Inclusion 
criteria were the following: 1) histologically confirmed 
diagnosis of breast cancer, 2) 5 or fewer metastatic lesions, 
3) no brain metastases, 4) primary tumor controlled. 
Radiotherapeutic treatment was SBRT (30-45 Gy in 3 
fractions) or fractionated IMRT (40-60 Gy in 15-25 fractions). 
Primary endpoint was PFS; secondary endpoints were local-
control (LC), overall survival (OS), and toxicity, which was 
assessed using the CTCAE v4.0 scale. 
 
Results: The analysis was conducted on 37 patients. The 
median age was 55 years. Twenty-five (68%) had 
oligometastatic disease at diagnosis, and 12 (32%) had the 
oligometastatic status induced by systemic treatment. 
Sixteen (43%) patients had a single metastasis, and 21 (47%) 
had 2 or more lesions. Thirty-one (84%) patients were treated 
with SBRT and 6 (16%) with fractionated IMRT. With a median 
follow-up of 18 months, 1-year and 2-year PFS was 74% and 
44%, respectively. No differences was seen in PFS between 
patients with only 1 metastases vs. those with ≥2 metastases, 
or between patients treated with SBRT vs. fractionated IMRT. 
Only two patients experienced local failure. One of these two 
patients had an isolated local failure for a spinal lesion that 
was treated with a minimum dose of 17 Gy in 3 fractions 
(being the spinal cord constraint prior on the PTV coverage). 
Two-year LC was 96%. Two patients died of disease, and 2-
year OS was 96%. The proposed treatment was well 
tolerated; no Grade ≥3 toxicity was documented. Two 
patients experienced Grade 2 pain, 4 Grade 1 pain, and 2 
developed Grade 2 fatigue. 
 
Conclusion: Radical radiotherapy delivered to all the 
metastatic sites in oligometastatic breast cancer patients led 
to promising results in terms of local control and progression-
free survival. Treatment was well tolerated. The results of 
this study may motivate for conducting phase III trials. 
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Purpose or Objective: Previous studies have shown an 
increased risk of ischemic heart disease in breast cancer 
patients treated with radiotherapy (RT). It has recently been 
reported that the risk of major coronary events increases per 
gray of mean radiation dose delivered to the heart for 
patients undergoing either left- or right-sided breast RT. 
However, the anatomy of cardiovascular damage related to 
right-sided breast RT has not been well-described, 
specifically for radiation dose delivered to the right coronary 
artery (RCA). This may be of particular relevance for regional 
nodal irradiation that includes the internal mammary nodes 
(IMNs). In this prospective planning study, the impact of IMN 
irradiation on the RCA and organs at risk (OAR) in patients 
undergoing right-sided post-mastectomy RT (PMRT) was 
assessed. 
 
Material and Methods: CT simulation scans of 60 right-sided 
post-mastectomy patients were identified from an 
institutional database. In 30 cases, the IMNs were contoured 
from the 1st to 3rd intercostal space with a PTV of 5 mm. 
The RCA, heart, lungs and contralateral breast were 
delineated as OARs. A four-field modified wide tangent 
photon plan was created encompassing the chestwall, IMNs, 
supraclavicular fossa and axilla. For the remaining 30 
patients (control group), a four-field plan that excluded the 
IMNs was generated. All patients were planned to receive 50 
Gy in 25 fractions over 5 weeks. Doses were compared 
between the two groups utilizing the Mann-Whitney test to 
determine whether there was a statistically significant 
difference in dose to OARs between these groups. 
 
Results: In the group with IMN treatment, 95% of prescribed 
dose to the IMN PTV covered a median volume of 99% (range 
90-100). There was a significant increase in dose to the RCA 
in the IMN treated group compared to the control group. The 
maximum dose to the RCA (3.33 Gy vs 2.35 Gy, p<0.0001) and 
mean RCA dose (2.41 Gy vs 1.69 Gy, p<0.0001) were both 
increased. Similarly, the mean heart dose (MHD) was 
increased (1.3 Gy vs 1.09 Gy, p<0.022). Inclusion of the IMNs 
increased lung V20 (18 Gy vs 15 Gy, p<0.00021) and mean 
lung dose (9.1 Gy vs 8.09 Gy, p<0.00051). There was a 
significant increase in the volume of contralateral breast 
receiving 3 Gy in the group requiring IMN treatment (3.75 Gy 
vs 0 Gy, p<0.0001). 
 
Conclusion: Inclusion of the IMNs in patients undergoing 
PMRT significantly increases radiation dose to the RCA and 
MHD. An acceptable dose to the RCA has not been well-
established but should be as low as is reasonably achievable. 
The dose and clinical implications of radiation to the RCA 
needs further evaluation in prospective studies utilizing 
techniques to minimize cardiac exposure. 
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